pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Canada clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
Taiho Pharma Canada projects
16 ClinicalTrials.gov programs sponsored by Taiho Pharma Canada.
Taiho Pharma Canada has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ASTX030-01
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Futibatinib, FULVESTRANT
Taiho Pharma Netherlands B.V.
Malignant Solid Tumors
1 trial -
TAS6417-301
Taiho Pharma Netherlands B.V.
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
1 trial -
TAS6417-302
Taiho Pharma Netherlands B.V.
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
1 trial -
ASTX727
Taiho Pharma Netherlands B.V.
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors
1 trial -
ASTX727-07
Taiho Pharma Netherlands B.V.
Acute Myeloid Leukemia (AML)
1 trial -
TAS-120
Taiho Pharma Netherlands B.V.
Advanced Cholangiocarcinoma
1 trial -
TAS-120-203
Taiho Pharma Netherlands B.V.
Advanced or Metastatic Urothelial Carcinoma
1 trial -
TAS-120-206
Taiho Pharma Netherlands B.V.
Solid Tumors
1 trial -
TAS-205
Taiho Pharma Netherlands B.V.
Duchenne Muscular Dystrophy
1 trial -
TAS-303
Taiho Pharma Netherlands B.V.
Stress Urinary Incontinence
1 trial -
Tolinapant, Tolinapant
Taiho Pharma Netherlands B.V.
Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy
1 trial -
ASTX727-03
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS)
1 trial -
ASTX727-17
Taiho Pharma Netherlands B.V.
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors
1 trial -
ASTX727-18
Taiho Pharma Netherlands B.V.
Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)
1 trial -
TAS0612-101
Taiho Pharma Netherlands B.V.
Locally Advanced or Metastatic Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does Taiho Pharma Canada have?
16 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.